Stockholm, Sweden, November 17, 2026
Sine Health has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Sine, its smartphone-based essential tremor monitoring system, introducing a new digital healthcare solution for monitoring neurological symptoms during everyday activities. The regulatory clearance, identified under 510(k) number K261026, makes Sine the first FDA-cleared system designed to monitor essential tremor using only a smartphone, according to the company. The technology uses sensors already integrated into patients’ smartphones to passively measure tremor movements while individuals go about their daily routines. Unlike conventional clinical assessments that rely heavily on brief observations during hospital or clinic visits, the system is designed to provide healthcare professionals with objective information about changes in tremor between appointments. Essential tremor affects approximately 7 million people in the United States, making it one of the most common movement disorders. The new clearance represents an important development in digital neurology and expands the application of smartphone-based medical monitoring technologies.
FDA Clearance Introduces Smartphone-Based Tremor Monitoring
The FDA’s 510(k) clearance enables Sine Health to advance its smartphone-based essential tremor monitoring system in the U.S. medical technology market. The device, identified in the FDA database as Sine Monitoring Essential Tremor Smartphone (SMETSP), received a substantially equivalent decision on November 15, 2026. The system is designed to operate using sensors already available in compatible smartphones, eliminating the need for patients to purchase a dedicated wearable monitoring device. Similar to a step-counting application, Sine runs in the background and collects movement-related information during normal daily activities. This passive monitoring approach is intended to capture tremor patterns beyond the limited observation periods available during routine clinical consultations. The resulting information can help clinicians understand how symptoms change over time and provide additional information when evaluating treatment response. According to Sine Health, the technology addresses an important limitation in essential tremor management, as treatment decisions are often based on intermittent clinical assessments rather than continuous information about patients’ daily experiences. By making smartphone-based monitoring available through an FDA-cleared medical device, the company aims to support more informed neurological assessments and improve the availability of objective symptom information.
Essential Tremor Monitoring Supports Better Clinical Assessment
Essential tremor is a neurological movement disorder characterized by involuntary rhythmic shaking, particularly affecting the hands and arms, although other body parts can also be involved. Symptoms may interfere with everyday activities such as eating, writing, drinking and performing routine tasks. Treatment options include medications and, for selected patients, surgical or device-based interventions. However, determining the effectiveness of treatment can be challenging when symptom assessments are limited to occasional clinic visits. Sine Health’s monitoring platform aims to address this challenge by collecting movement information during patients’ everyday activities and presenting clinicians with a more comprehensive view of tremor patterns between appointments. The company believes this information could support treatment optimization as additional therapeutic options for essential tremor become available. Jakob Gerstl, MBBS, MPH, founder and CEO of Sine Health, highlighted the growing importance of measuring how patients experience their symptoms outside healthcare facilities. The availability of objective monitoring information may help clinicians assess changes over time and better understand individual treatment responses. However, the smartphone monitoring system is intended to supplement professional medical assessment rather than independently diagnose essential tremor or determine treatment decisions.
Second FDA Clearance Strengthens Sine Health’s Digital Neurology Portfolio
The latest regulatory milestone represents Sine Health’s second FDA clearance since the company’s establishment, following its earlier authorization in June 2026 for a Parkinson’s disease monitoring system using Apple Watch technology. The earlier system was designed to monitor tremor and dyskinesia associated with Parkinson’s disease, while the newly cleared product focuses on essential tremor monitoring using smartphone sensors alone. Together, these regulatory milestones demonstrate the company’s strategy of developing digital neurological assessment solutions using consumer technology platforms. Formerly known as Nordic Kinetics, Sine Health develops technology that converts smartphone and wearable sensor data into continuous, objective neurological measurements. Its broader platform aims to support clinicians in evaluating symptoms, monitoring treatment responses and following disease progression over time. The company sees significant opportunities for digital monitoring as neurological treatment options continue to evolve and healthcare providers increasingly seek reliable information from patients’ daily lives. The FDA clearance of Sine’s essential tremor monitoring system marks a significant step forward in smartphone-based neurological monitoring, bringing digital health technology closer to routine clinical assessment. By combining existing smartphone sensors with passive tremor measurement, Sine Health aims to expand access to objective neurological information and support more informed care for people living with essential tremor.
Source: Sine Health press release



